Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
Saved in:
| Title: | Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T. |
|---|---|
| Authors: | Tsao AS; The University of Texas MD Anderson Cancer Center, Houston, TX., Song Z; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Ho AL; Memorial Sloan Kettering Cancer Center, New York, NY., Mehnert JM; Laura and Issac Perlmutter Cancer Center, New York, NY., Ivy P; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Dana-Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Rockville, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Hamilton SR; City of Hope National Medical Center, Duarte, CA., Takebe N; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Ajumally R; University of Oklahoma Health Science Center, Oklahoma City, OK., Silhavy J; Illumina, Inc, San Diego, CA., Rahmanian S; Illumina, Inc, San Diego, CA., Das B; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD., Chen L; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD., Karlovich C; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD., Lococo JS; Illumina, Inc, San Diego, CA., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; University of TX Southwestern Medical Center, Dallas, TX., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Pennsylvania Hospital, Philadelphia, PA., Chen AP; Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital, Boston, MA. |
| Source: | JCO precision oncology [JCO Precis Oncol] 2025 Oct; Vol. 9, pp. e2500119. Date of Electronic Publication: 2025 Oct 09. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
